Superworth

Biocryst Pharmaceuticals price to free cash flow BCRX

Market value divided by free cash flow over the last twelve months, since 2025.

Today, Oct 23, 2026
5.2×
Peer median
31.1×

Biocryst Pharmaceuticals' price to free cash flow is 5.2× as of Oct 23, 2026.

The median for 10 biotech stocks of a similar size is 31.1×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.2×5.2×33.0×
202533.6×30.7×114×

Against its peers

Companies in Biotechnology nearest Biocryst Pharmaceuticals' size, closest first, today.

CompanyPrice to free cash flow
BCRXBiocryst Pharmaceuticals5.2×
VCELVericel35.3×
ADMAAdma Biologics20.5×
MGTXMeiraGTx84.5×
KRYSKrystal Biotech35.8×
RGENRepligen89.2×
TECHBIO-TECHNE43.2×
HALOHalozyme Therapeutics17.7×
NBIXNeurocrine Biosciences16.7×
EXELExelixis13.6×
PLXProtalix BioTherapeutics26.8×
Peer median31.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Biocryst Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.